Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 3/2021

01-03-2021 | Arterial Occlusive Disease | Vascular Biology (H. Pownall, Section Editor)

The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis

Authors: Xian-Cheng Jiang, Yang Yu

Published in: Current Atherosclerosis Reports | Issue 3/2021

Login to get access

Abstract

Purpose of Review

Phospholipid transfer protein (PLTP), a member of lipid transfer protein family, is an important protein involved in lipid metabolism in the circulation. This article reviews recent PLTP research progresses, involving lipoprotein metabolism and atherogenesis.

Recent Findings

PLTP activity influences atherogenic and anti-atherogenic lipoprotein levels. Human serum PLTP activity is a risk factor for human cardiovascular disease and is an independent predictor of all-cause mortality. PLTP deficiency reduces VLDL and LDL levels and attenuates atherosclerosis in mouse models, while PLTP overexpression exerts an opposite effect. Both PLTP deficiency and overexpression result in reduction of HDL which has different size, inflammatory index, and lipid composition. Moreover, although both PLTP deficiency and overexpression reduce cholesterol efflux capacity, but this effect has no impact in macrophage reverse cholesterol transport in mice. Furthermore, PLTP activity is related with metabolic syndrome, thrombosis, and inflammation.

Summary

PLTP could be target for the treatment of dyslipidemia and atherosclerosis, although some potential off-target effects should be noted.
Literature
1.
Bruce C, Beamer LJ, Tall AR. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol. 1998;8:426–34.PubMedCrossRef
2.
Kleiger G, Beamer LJ, Grothe R, Mallick P, Eisenberg D. The 1.7 A crystal structure of BPI: a study of how two dissimilar amino acid sequences can adopt the same fold. J Mol Biol. 2000;299:1019–34.PubMedCrossRef
3.
Qiu X, Mistry A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14:106–13.PubMedCrossRef
4.
Eckert JK, Kim YJ, Kim JI, Gurtler K, Oh DY, Sur S, et al. The crystal structure of lipopolysaccharide binding protein reveals the location of a frequent mutation that impairs innate immunity. Immunity. 2013;39:647–60.PubMedCrossRef
5.
Day JR, Albers JJ, Lofton-Day CE, Gilbert TL, Ching AF, Grant FJ, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem. 1994;269:9388–91.PubMedCrossRef
6.
Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem. 1995;270:17133–8.PubMedCrossRef
7.
Massey JB, Hickson D, She HS, Sparrow JT, Via DP, Gotto AM Jr, et al. Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim Biophys Acta. 1984;794:274–80.PubMedCrossRef
8.
Yu Y, Guo S, Feng Y, Feng L, Cui Y, Song G, et al. Phospholipid transfer protein deficiency decreases the content of S1P in HDL via the loss of its transfer capability. Lipids. 2014;49:183–90.PubMedCrossRef
9.
Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res. 2003;44:1453–61.PubMedCrossRef
10.
O’Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 2003;108:270–4.PubMedCrossRef
11.
Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000;41:1651–7.PubMedCrossRef
12.
Cheung MC, Albers JJ. Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. J Lipid Res. 2006;47:1315–21.PubMedCrossRef
13.
Siggins S, Karkkainen M, Tenhunen J, Metso J, Tahvanainen E, Olkkonen VM, et al. Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res. 2004;45:387–95.PubMedCrossRef
14.
Yazdanyar A, Jiang XC. Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice. Hepatology. 2012;56:576–84.PubMedCrossRef
15.
Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, et al. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol. 2007;27:578–86.PubMedCrossRef
16.
Jiang H, Yazdanyar A, Lou B, Chen Y, Zhao X, Li R, et al. Adipocyte phospholipid transfer protein and lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2015;35:316–22.PubMedCrossRef
17.
Sponton CH, Hosono T, Taura J, Jedrychowski MP, Yoneshiro T, Wang Q, et al. The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. EMBO Rep. 2020;21:e49828.PubMedCrossRefPubMedCentral
18.
Jiang XC, D’Armiento J, Mallampalli RK, Mar J, Yan SF, Lin M. Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia. J Biol Chem. 1998;273:15714–8.PubMedCrossRef
19.
20.
Vuletic S, Kennedy H, Albers JJ, Killestein J, Vrenken H, Lutjohann D, et al. Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Mult Scler Relat Disord. 2014;3:533–41.PubMedPubMedCentralCrossRef
21.
Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ. Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer’s disease. J Lipid Res. 2003;44:1113–23.PubMedCrossRef
22.
Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, et al. Reduced CSF PLTP activity in Alzheimer’s disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res. 2005;80:406–13.PubMedCrossRef
23.
Desrumaux C, Pisoni A, Meunier J, Deckert V, Athias A, Perrier V, et al. Increased amyloid-beta peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice. Neuropsychopharmacology. 2013;38:817–25.PubMedPubMedCentralCrossRef
24.
Chirackal Manavalan AP, Kober A, Metso J, Lang I, Becker T, Hasslitzer K, et al. Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier. J Biol Chem. 2014;289:4683–98.PubMedCrossRef
25.
Zhou T, He Q, Tong Y, Zhan R, Xu F, Fan D, et al. Phospholipid transfer protein (PLTP) deficiency impaired blood-brain barrier integrity by increasing cerebrovascular oxidative stress. Biochem Biophys Res Commun. 2014;445:352–6.PubMedCrossRef
26.
Tu AY, Albers JJ. Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene. Biochem Biophys Res Commun. 2001;287:921–6.PubMedCrossRef
27.
Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem. 2002;277:39561–5.PubMedCrossRef
28.
Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol. 2003;23:2182–91.PubMedPubMedCentralCrossRef
29.
Urizar NL, Dowhan DH, Moore DD. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem. 2000;275:39313–7.PubMedCrossRef
30.
Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes. 1999;48:1631–7.PubMedCrossRef
31.
Lalanne F, Motta C, Pafumi Y, Lairon D, Ponsin G. Modulation of the phospholipid transfer protein-mediated transfer of phospholipids by diacylglycerols. J Lipid Res. 2001;42:142–9.PubMedCrossRef
32.
Jin W, Wang X, Millar JS, Quertermous T, Rothblat GH, Glick JM, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 2007;6:129–36.PubMedPubMedCentralCrossRef
33.
• Yu Y, Lei X, Jiang H, Li Z, Creemers JWM, Zhang M, et al. Prodomain of furin promotes phospholipid transfer protein proteasomal degradation in hepatocytes. J Am Heart Assoc. 2018;7(9):e008526. This paper indicated that profurin-mediated PLTP hepatocyte intracellular degradation plays an important role in VLDL production.
34.
Guo LL, Chen YJ, Wang T, An J, Wang CN, Shen YC, et al. Ox-LDL-induced TGF-beta1 production in human alveolar epithelial cells: involvement of the Ras/ERK/PLTP pathway. J Cell Physiol. 2012;227:3185–91.PubMedCrossRef
35.
Chai XM, Li YL, Chen H, Guo SL, Shui LL, Chen YJ. Cigarette smoke extract alters the cell cycle via the phospholipid transfer protein/transforming growth factor-beta1/CyclinD1/CDK4 pathway. Eur J Pharmacol. 2016;786:85–93.PubMedCrossRef
36.
Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:1857–62.PubMedCrossRef
37.
de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BH, van Tol A, Dullaart RP. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia. 2006;49:398–404.PubMedCrossRef
38.
Dullaart RP, van Tol A, Dallinga-Thie GM. Phospholipid transfer protein, an emerging cardiometabolic risk marker: is it time to intervene? Atherosclerosis. 2013;228:38–41.PubMedCrossRef
39.
Colhoun HM, Scheek LM, Rubens MB, Van Gent T, Underwood SR, Fuller JH, et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes. 2001;50:652–9.PubMedCrossRef
40.
Schlitt A, Blankenberg S, Bickel C, Lackner KJ, Heine GH, Buerke M, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res. 2009;50:723–9.PubMedPubMedCentralCrossRef
41.
Vergeer M, Boekholdt SM, Sandhu MS, Ricketts SL, Wareham NJ, Brown MJ, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation. 2010;122:470–7.PubMedCrossRef
42.
Robins SJ, Lyass A, Brocia RW, Massaro JM, Vasan RS. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study Atherosclerosis. 2013;228:230–6.PubMed
43.
Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis. 2009;207:261–5.PubMedPubMedCentralCrossRef
44.
Chen X, Sun A, Zou Y, Ge J, Kamran H, Jiang XC, et al. High PLTP activity is associated with depressed left ventricular systolic function. Atherosclerosis. 2013;228:438–42.PubMedCrossRef
45.
Cavusoglu E, Marmur JD, Chhabra S, Hojjati MR, Yanamadala S, Chopra V, et al. Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease. Atherosclerosis. 2015;239:503–8.PubMedPubMedCentralCrossRef
46.
Yatsuya H, Tamakoshi K, Hattori H, Otsuka R, Wada K, Zhang H, et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J. 2004;68:11–6.PubMedCrossRef
47.
Huuskonen J, Ekstrom M, Tahvanainen E, Vainio A, Metso J, Pussinen P, et al. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis. 2000;151:451–61.PubMedCrossRef
48.
Dullaart RP, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest. 2004;64:205–15.PubMedCrossRef
49.
Ruhling K, Lang A, Richard F, Van Tol A, Eisele B, Herzberg V, et al. Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. Metabolism. 1999;48:1361–6.PubMedCrossRef
50.
Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 2008;196:219–26.PubMedCrossRef
51.
Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001;7:847–52.PubMedCrossRef
52.
Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol. 2003;23:1601–7.PubMedCrossRef
53.
van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem. 2002;277:48938–43.PubMedCrossRef
54.
van Haperen R, van Gent T, van Tol A, de Crom R. Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice. Atherosclerosis. 2013;227:37–42.PubMedCrossRef
55.
Desrumaux C, Deckert V, Lemaire-Ewing S, Mossiat C, Athias A, Vandroux D, et al. Plasma phospholipid transfer protein deficiency in mice is associated with a reduced thrombotic response to acute intravascular oxidative stress. Arterioscler Thromb Vasc Biol. 2010;30:2452–7.PubMedCrossRef
56.
Deckert V, Kretz B, Habbout A, Raghay K, Labbe J, Abello N, et al. Development of abdominal aortic aneurysm is decreased in mice with plasma phospholipid transfer protein deficiency. Am J Pathol. 2013;183:975–86.PubMedCrossRef
57.
Masson D, Deckert V, Gautier T, Klein A, Desrumaux C, Viglietta C, et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. Arterioscler Thromb Vasc Biol. 2011;31:766–74.PubMedCrossRef
58.
Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699–705.PubMedCrossRef
59.
Hoekstra M, van der Sluis RJ, Hildebrand RB, Lammers B, Zhao Y, Pratico D, et al. Disruption of phospholipid transfer protein-mediated high-density lipoprotein maturation reduces scavenger receptor BI deficiency-driven atherosclerosis susceptibility despite unexpected metabolic complications. Arterioscler Thromb Vasc Biol. 2020;40:611–23.PubMedCrossRef
60.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–13.PubMedPubMedCentralCrossRef
61.
Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res. 2002;43:1875–80.PubMedCrossRef
62.
van Haperen R, Samyn H, van Gent T, Zonneveld AJ, Moerland M, Grosveld F, et al. Novel roles of hepatic lipase and phospholipid transfer protein in VLDL as well as HDL metabolism. Biochim Biophys Acta. 1791;2009:1031–6.
63.
Okazaki H, Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem. 2010;285:6801–10.PubMedCrossRef
64.
Manchekar M, Liu Y, Sun Z, Richardson PE, Dashti N. Phospholipid transfer protein plays a major role in the initiation of apolipoprotein B-containing lipoprotein assembly in mouse primary hepatocytes. J Biol Chem. 2015;290:8196–205.
65.
Yazdanyar A, Quan W, Jin W, Jiang XC. Liver-specific phospholipid transfer protein deficiency reduces high-density lipoprotein and non-high-density lipoprotein production in mice. Arterioscler Thromb Vasc Biol. 2013;33:2058–64.PubMedPubMedCentralCrossRef
66.
Masson D, Deckert V, Gautier T, Klein A, Desrumaux C, Viglietta C, et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. Arterioscler Thromb Vasc Biol. 2011;31:766–74
67.
Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.PubMedCrossRef
68.
69.
Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907–14.PubMedPubMedCentralCrossRef
70.
Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res. 2000;41:269–76.PubMedCrossRef
71.
Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res. 2004;45:1852–8.PubMedCrossRef
72.
Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30:139–43.PubMedCrossRef
73.
Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem. 2003;278:52379–85.PubMedCrossRef
74.
Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268:4032–6.PubMedCrossRef
75.
Huuskonen J, Olkkonen VM, Ehnholm C, Metso J, Julkunen I, Jauhiainen M. Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion. Biochemistry. 2000;39:16092–8.PubMedCrossRef
76.
Rye KA, Jauhiainen M, Barter PJ, Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res. 1998;39:613–22.PubMedCrossRef
77.
Tall AR, Hogan V, Askinazi L, Small DM. Interaction of plasma high density lipoproteins with dimyristoyllecithin multilamellar liposomes. Biochemistry. 1978;17:322–6.PubMedCrossRef
78.
Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res. 1985;26:842–51.PubMedCrossRef
79.
Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem. 1997;272:27393–400.PubMed
80.
van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:1082–8.PubMedCrossRef
81.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.PubMedCrossRef
82.
Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–30.PubMedCrossRef
83.
Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–60.PubMedCrossRef
84.
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547–59.PubMedPubMedCentralCrossRef
85.
86.
Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–80.PubMedPubMedCentralCrossRef
87.
Kuwano T, Bi X, Cipollari E, Yasuda T, Lagor WR, Szapary HJ, et al. Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. J Lipid Res. 2017;58:731–41.PubMedPubMedCentralCrossRef
88.
Sachinidis A, Kettenhofen R, Seewald S, Gouni-Berthold I, Schmitz U, Seul C, et al. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler Thromb Vasc Biol. 1999;19:2412–21.PubMedCrossRef
89.
Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780–5.PubMedCrossRef
90.
Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis. 2005;178:199–205.PubMedCrossRef
91.
Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50–60.PubMedCrossRef
92.
93.
Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011;108:9613–8.PubMedPubMedCentralCrossRef
94.
Bosteen MH, Madsen Svarrer EM, Bisgaard LS, Martinussen T, Madsen M, Nielsen LB, et al. Effects of apolipoprotein M in uremic atherosclerosis. Atherosclerosis. 2017;265:93–101.PubMedCrossRef
95.
Obinata H, Kuo A, Wada Y, Swendeman S, Liu CH, Blaho VA, et al. Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice. J Lipid Res. 2019;60:1912–21.PubMedPubMedCentralCrossRef
96.
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin N Am. 2014;43:1–23.CrossRef
97.
Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Investig. 1994;24:188–94.CrossRef
98.
Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res. 2000;41:237–44.PubMedCrossRef
99.
Kaser S, Sandhofer A, Foger B, Ebenbichler CF, Igelseder B, Malaimare L, et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia. 2001;44:1111–7.PubMedCrossRef
100.
Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem. 1999;274:4140–6.PubMedCrossRef
101.
Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem. 2005;280:18336–40.PubMedCrossRef
102.
Song G, Zong C, Shao M, Yu Y, Liu Q, Wang H, et al. Phospholipid transfer protein (PLTP) deficiency attenuates high fat diet induced obesity and insulin resistance. Biochim Biophys Acta Mol Cell Biol Lipids. 1864;2019:1305–13.
103.
Sponton CH, Hosono T, Taura J, Jedrychowski MP, Yoneshiro T, Wang Q, et al. The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. EMBO Rep. 2020;21:e49828.
104.
Klein A, Deckert V, Schneider M, Dutrillaux F, Hammann A, Athias A, et al. Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: relevance in phospholipid transfer protein-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2160–7.PubMedCrossRef
105.
Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, Dahlback B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem. 2009;284:5896–904.PubMedCrossRef
106.
Deguchi H, Wolfbauer G, Cheung MC, Banerjee Y, Elias DJ, Fernandez JA, et al. Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thromb J. 2015;13:24.PubMedPubMedCentralCrossRef
107.
•• Zhao XM, Wang Y, Yu Y, Jiang H, Babinska A, Chen XY, et al. Plasma phospholipid transfer protein promotes platelet aggregation. Thromb Haemost. 2018;118:2086–97 This paper showed that PLTP can promote platelet aggregation and PLTP is a factor mediating hypercoagulation.PubMedCrossRefPubMedCentral
108.
Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta. 1733;2005:187–91.
109.
Shelly L, Royer L, Sand T, Jensen H, Luo Y. Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice. J Lipid Res. 2008;49:773–81.PubMedCrossRef
110.
Desrumaux C, Lemaire-Ewing S, Ogier N, Yessoufou A, Hammann A, Sequeira-Le Grand A, et al. Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization. Cell Mol Immunol. 2016;13:795–804.PubMedCrossRef
111.
Gautier T, Klein A, Deckert V, Desrumaux C, Ogier N, Sberna AL, et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem. 2008;283:18702–10.PubMedCrossRef
112.
Brehm A, Geraghty P, Campos M, Garcia-Arcos I, Dabo AJ, Gaffney A, et al. Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation. FASEB J. 2014;28:2318–31.PubMedPubMedCentralCrossRef
113.
Vuletic S, Dong W, Wolfbauer G, Tang C, Albers JJ. PLTP regulates STAT3 and NFkappaB in differentiated THP1 cells and human monocyte-derived macrophages. Biochim Biophys Acta. 1813;2011:1917–24.
114.
Yu Y, Cui Y, Zhao Y, Liu S, Song G, Jiao P, et al. The binding capability of plasma phospholipid transfer protein, but not HDL pool size, is critical to repress LPS induced inflammation. Sci Rep. 2016;6:20845.PubMedPubMedCentralCrossRef
115.
Oram JF, Wolfbauer G, Tang C, Davidson WS, Albers JJ. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J Biol Chem. 2008;283:11541–9.PubMedPubMedCentralCrossRef
Metadata
Title
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis
Authors
Xian-Cheng Jiang
Yang Yu
Publication date
01-03-2021
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 3/2021
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-021-00907-6

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits